CEO Joseph Belanoff was paid $15,303,551 in fiscal year 2025, ↑ up 54.7% from fiscal year 2024 (SEC filing 0001628280-26-025735 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$15,303,551 ↑ Joseph Belanoff total, FY2025 | — CEO pay percentile vs peers | 46:1 CEO-to-median pay ratio | 94.08% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CORT's next annual pay disclosure, estimated April 9, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joseph Belanoff | $1,182,333 | $1,190,000 | $0 | $12,907,718 | $0 | $0 | $23,500 | $15,303,551 |
| Chief Executive Officer and President | ||||||||
| Charles Robb | 711,413 | 358,000 | 124,500 | 5,163,087 | 0 | 0 | 23,500 | 6,380,500 |
| Chief Business Officer and Secretary | ||||||||
| William Guyer | 706,387 | 429,600 | 17,871 | 5,163,087 | 0 | 0 | 23,500 | 6,340,445 |
| Chief Development Officer | ||||||||
| Sean Maduck | 648,860 | 261,200 | 111,995 | 5,163,087 | 0 | 0 | 23,500 | 6,208,642 |
| President, Corcept Endocrinology | ||||||||
| Atabak Mokari | 566,347 | 285,000 | 97,733 | 5,163,087 | 0 | 0 | 23,500 | 6,135,667 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joseph Belanoff | $15,303,551 | $9,890,081 | $9,337,734 | ↑ +5,413,470 |
| Charles Robb | 6,380,500 | 4,138,371 | 3,956,718 | ↑ +2,242,129 |
| William Guyer | 6,340,445 | — | 3,856,200 | — |
| Sean Maduck | 6,208,642 | 3,971,171 | 3,908,931 | ↑ +2,237,471 |
| Atabak Mokari | 6,135,667 | 3,857,306 | 3,717,107 | ↑ +2,278,361 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Corcept Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CORT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CORT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CORT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Joseph Belanoff | CEO | $15,303,551 |
| Atabak Mokari | CFO | $6,135,667 |
| Charles Robb | Executive | $6,380,500 |
| Sean Maduck | President | $6,208,642 |
| William Guyer | Chief Development Officer | $6,340,445 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Daniel N. Swisher Jr | Independent Director | $762,004 |
| David L. Mahoney | Independent Director | $784,504 |
| G. Leonard Baker Jr | Independent Director | $768,004 |
| Gillian M. Cannon | Former director (through FY2025) | $770,504 |
| Gregg Alton | Independent Director | $787,004 |
| James N. Wilson | Chair of the Board | $1,292,914 |
| Joshua M. Murray | Independent Director | $764,504 |
| Kimberly Park | Independent Director | $764,994 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Charles Robb | Chief Business Officer | 2026-05-13 | A | 1,000 | $0 | $0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-13 | D | 5,300 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-13 | A | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Joshua M. Murray | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel N. Swisher Jr | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Alton | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Leonard Baker Jr | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Mahoney | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | A | 9,011 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-27 | D | 600 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | A | 75,000 | 8 | 620,250 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | D | 9,011 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-05-27 | D | 5,000 | 65 | 325,000 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | D | 892,056 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 54,575 | 65 | 3,567,628 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 20,425 | 66 | 1,351,316 | Common, open-market sale | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | A | 150,000 | 0 | 0 | Common | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | A | 150,000 | 0 | 0 | Common | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | D | 300,000 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-06-01 | D | 12,837 | 70 | 895,252 | Common, indirect | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-01 | A | 776 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 634 | 70 | 44,659 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 40,000 | 19 | 770,400 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 3,931 | 71 | 278,103 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-01 | A | 877 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-01 | A | 537 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 634 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | D | 40,000 | 70 | 2,800,004 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 21,069 | 70 | 1,477,080 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-01 | A | 877 | 70 | 61,776 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-01 | A | 537 | 70 | 37,826 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 615 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 615 | 70 | 43,321 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-01 | A | 776 | 70 | 54,661 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-02 | D | 395 | 70 | 27,824 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-02 | D | 452 | 70 | 31,839 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-02 | D | 358 | 70 | 25,218 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-02 | D | 269 | 70 | 18,948 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | D | 20,000 | 71 | 1,412,000 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | A | 20,000 | 22 | 433,000 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 2 | 82 | 165 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 11,081 | 81 | 896,923 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 9,434 | 80 | 754,924 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 19,483 | 82 | 1,593,889 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | A | 40,000 | 19 | 770,400 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-06-16 | D | 4,177 | 83 | 345,416 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-06-16 | D | 5,823 | 84 | 486,633 | Common, indirect | Form 4 ↗ |
| David L. Mahoney | Director | 2026-06-17 | D | 20,000 | 85 | 1,690,506 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 2,801 | 89 | 247,924 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 11,024 | 87 | 962,780 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 11,175 | 89 | 998,033 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 19,048 | 93 | 1,773,481 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | A | 20,000 | 22 | 433,000 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 952 | 94 | 89,048 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 24,167 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 101 | 89 | 9,032 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 3,520 | 88 | 310,822 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 28,460 | 88 | 2,501,244 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | A | 24,167 | 23 | 557,291 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 1,978 | 89 | 177,007 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 1,079 | 87 | 93,633 | Common, indirect | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 15,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 7,919 | 87 | 687,179 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | A | 15,833 | 19 | 304,944 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 2,974 | 89 | 264,122 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 3,969 | 88 | 348,223 | Common, indirect | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,267 | 118 | 974,951 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 80,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 1,001 | 121 | 120,796 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 14,222 | 116 | 1,647,859 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 15,477 | 115 | 1,779,237 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 600 | 111 | 66,570 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,956 | 107 | 957,892 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | A | 80,000 | 23 | 1,844,800 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,103 | 120 | 971,939 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,700 | 113 | 531,941 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 400 | 108 | 43,384 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,783 | 119 | 567,908 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 7,089 | 117 | 829,102 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 2,202 | 110 | 242,282 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,200 | 106 | 443,248 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-08-03 | D | 1,540 | 114 | 175,806 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | D | 20,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | D | 20,305 | 115 | 2,329,075 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | A | 20,305 | 8 | 167,922 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | A | 3,700 | 22 | 80,105 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | D | 3,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | D | 3,700 | 113 | 418,562 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | D | 11,530 | 113 | 1,304,933 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | A | 16,300 | 22 | 352,895 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-10 | D | 1,031 | 115 | 118,068 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-10 | A | 1,031 | 8 | 8,526 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-10 | — | 1,031 | — | — | 1 insider, 1 accrual row | ||
| William Guyer | Chief Development Officer | 2026-08-10 | D | 16,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | D | 4,770 | 114 | 543,957 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | A | 3,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | D | 11,530 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | A | 3,000 | 0 | 0 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 4,668 | 111 | 520,214 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 3,053 | 110 | 337,341 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | D | 3,664 | 114 | 419,491 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 2,279 | 113 | 256,706 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | A | 3,664 | 8 | 30,301 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | D | 3,664 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-17 | D | 10,000 | 116 | 1,162,572 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-17 | D | 125 | 0 | 0 | Common | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 400 | 120 | 47,855 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 7,055 | 119 | 838,710 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 4,984 | 117 | 585,478 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 91,167 | 118 | 10,779,367 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 30,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | A | 30,955 | 11 | 351,339 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 5,870 | 126 | 739,965 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 25,085 | 125 | 3,147,355 | Common, open-market sale | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 26,685 | 123 | 3,270,169 | Common, open-market sale | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 3,315 | 122 | 404,728 | Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | A | 30,000 | 13 | 404,700 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-01 | A | 130 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-01 | A | 130 | 113 | 14,739 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-01 | A | 138 | 0 | 0 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-01 | A | 138 | 113 | 15,646 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-01 | A | 164 | 113 | 18,594 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-01 | A | 138 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-01 | A | 138 | 113 | 15,646 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 150 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-09-01 | A | 164 | 0 | 0 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-09-01 | A | 164 | 113 | 18,594 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 2,281 | 116 | 263,711 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 10,989 | 115 | 1,260,568 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-01 | A | 164 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 150 | 113 | 17,007 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 11,730 | 114 | 1,336,459 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 58,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 23,600 | 109 | 2,580,674 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-02 | D | 91 | 113 | 10,318 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 23,770 | 111 | 2,631,349 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 102 | 113 | 11,565 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,537 | 111 | 171,181 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-02 | D | 72 | 113 | 8,163 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 5,621 | 115 | 644,042 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,606 | 114 | 182,632 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 974 | 112 | 109,474 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | A | 58,333 | 22 | 1,261,743 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-02 | D | 102 | 113 | 11,565 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-02 | D | 117 | 113 | 13,265 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,225 | 115 | 141,413 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 2,596 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | A | 2,596 | 11 | 29,465 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 2,188 | 114 | 249,686 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | A | 7,404 | 14 | 100,398 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 7,404 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 7,812 | 113 | 885,261 | Common, open-market sale | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 6,800 | 110 | 749,835 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 400 | 111 | 44,335 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 2,800 | 112 | 312,771 | Common, indirect | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-16 | D | 296 | 101 | 29,843 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-17 | A | 17,493 | 8 | 144,667 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-17 | D | 17,493 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | A | 5,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | A | 5,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | D | 17,100 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-01 | — | 1,223 | — | — | 2 insiders, 2 accrual rows | ||
| Sean Maduck | See Remarks | 2026-10-01 | A | 413 | 8 | 3,416 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-01 | D | 810 | 115 | 93,473 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-01 | A | 810 | 14 | 10,984 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-01 | D | 413 | 116 | 47,717 | Common, open-market sale | Form 4 ↗ |
| Justin Frederick Gunn | See Remarks | 2026-10-01 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 24,587 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 8,744 | 117 | 1,019,143 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 15,843 | 116 | 1,839,741 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | A | 24,587 | 8 | 203,334 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 8,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 5,147 | 117 | 600,063 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 2,086 | 116 | 241,412 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 1,100 | 115 | 125,973 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | A | 8,333 | 22 | 180,243 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 5,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 3,357 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 4,744 | 117 | 552,869 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 4,446 | 116 | 514,389 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | A | 5,833 | 19 | 112,344 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | A | 3,357 | 14 | 45,521 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 300 | 116 | 34,889 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 3,046 | 115 | 351,476 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 6,654 | 114 | 761,717 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Charles Robb | Chief Business Officer | 2026-05-13 | A | 1,000 | $0 | $0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-13 | D | 5,300 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-13 | A | 1,000 | 0 | 0 | Common | Form 4 ↗ |
| Joshua M. Murray | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel N. Swisher Jr | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg Alton | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| G. Leonard Baker Jr | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Mahoney | Director | 2026-05-21 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | A | 9,011 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-05-27 | D | 600 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | A | 75,000 | 8 | 620,250 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | D | 9,011 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-05-27 | D | 5,000 | 65 | 325,000 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-05-27 | D | 892,056 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 54,575 | 65 | 3,567,628 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-05-27 | D | 20,425 | 66 | 1,351,316 | Common, open-market sale | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | A | 150,000 | 0 | 0 | Common | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | A | 150,000 | 0 | 0 | Common | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-05-29 | D | 300,000 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Joseph K. Belanoff | Director | 2026-06-01 | D | 12,837 | 70 | 895,252 | Common, indirect | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-01 | A | 776 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 634 | 70 | 44,659 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 40,000 | 19 | 770,400 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 3,931 | 71 | 278,103 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-01 | A | 877 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-01 | A | 537 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | A | 634 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-01 | D | 40,000 | 70 | 2,800,004 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | D | 21,069 | 70 | 1,477,080 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-01 | A | 877 | 70 | 61,776 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-01 | A | 537 | 70 | 37,826 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 615 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-01 | A | 615 | 70 | 43,321 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-01 | A | 776 | 70 | 54,661 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-02 | D | 395 | 70 | 27,824 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-06-02 | D | 452 | 70 | 31,839 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-06-02 | D | 358 | 70 | 25,218 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-06-02 | D | 269 | 70 | 18,948 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | D | 20,000 | 71 | 1,412,000 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-06-02 | A | 20,000 | 22 | 433,000 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 2 | 82 | 165 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 11,081 | 81 | 896,923 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 9,434 | 80 | 754,924 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | D | 19,483 | 82 | 1,593,889 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-06-15 | A | 40,000 | 19 | 770,400 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-06-16 | D | 4,177 | 83 | 345,416 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-06-16 | D | 5,823 | 84 | 486,633 | Common, indirect | Form 4 ↗ |
| David L. Mahoney | Director | 2026-06-17 | D | 20,000 | 85 | 1,690,506 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 2,801 | 89 | 247,924 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 11,024 | 87 | 962,780 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-07-01 | D | 11,175 | 89 | 998,033 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 19,048 | 93 | 1,773,481 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | A | 20,000 | 22 | 433,000 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-07-07 | D | 952 | 94 | 89,048 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 24,167 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 101 | 89 | 9,032 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 3,520 | 88 | 310,822 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 28,460 | 88 | 2,501,244 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | A | 24,167 | 23 | 557,291 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 1,978 | 89 | 177,007 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 1,079 | 87 | 93,633 | Common, indirect | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 15,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | D | 7,919 | 87 | 687,179 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-15 | A | 15,833 | 19 | 304,944 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 2,974 | 89 | 264,122 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-07-15 | D | 3,969 | 88 | 348,223 | Common, indirect | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,267 | 118 | 974,951 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 80,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 1,001 | 121 | 120,796 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 14,222 | 116 | 1,647,859 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 15,477 | 115 | 1,779,237 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 600 | 111 | 66,570 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,956 | 107 | 957,892 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | A | 80,000 | 23 | 1,844,800 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 8,103 | 120 | 971,939 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,700 | 113 | 531,941 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 400 | 108 | 43,384 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,783 | 119 | 567,908 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 7,089 | 117 | 829,102 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 2,202 | 110 | 242,282 | Common, open-market sale | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-07-30 | D | 4,200 | 106 | 443,248 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-08-03 | D | 1,540 | 114 | 175,806 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | D | 20,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | D | 20,305 | 115 | 2,329,075 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-03 | A | 20,305 | 8 | 167,922 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | A | 3,700 | 22 | 80,105 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | D | 3,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-04 | D | 3,700 | 113 | 418,562 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | D | 11,530 | 113 | 1,304,933 | Common, open-market sale | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | A | 16,300 | 22 | 352,895 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-10 | D | 1,031 | 115 | 118,068 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-10 | A | 1,031 | 8 | 8,526 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-10 | D | 1,031 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | D | 16,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-08-10 | D | 4,770 | 114 | 543,957 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | A | 3,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | D | 11,530 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-12 | A | 3,000 | 0 | 0 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 4,668 | 111 | 520,214 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 3,053 | 110 | 337,341 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | D | 3,664 | 114 | 419,491 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-08-14 | D | 2,279 | 113 | 256,706 | Common, indirect | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | A | 3,664 | 8 | 30,301 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-14 | D | 3,664 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-17 | D | 10,000 | 116 | 1,162,572 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-08-17 | D | 125 | 0 | 0 | Common | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 400 | 120 | 47,855 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 7,055 | 119 | 838,710 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 4,984 | 117 | 585,478 | Common, open-market sale | Form 4 ↗ |
| David L. Mahoney | Director | 2026-08-18 | D | 91,167 | 118 | 10,779,367 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 30,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | A | 30,955 | 11 | 351,339 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 5,870 | 126 | 739,965 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-08-25 | D | 25,085 | 125 | 3,147,355 | Common, open-market sale | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 26,685 | 123 | 3,270,169 | Common, open-market sale | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | D | 3,315 | 122 | 404,728 | Common | Form 4 ↗ |
| Kimberly Park | Director | 2026-08-26 | A | 30,000 | 13 | 404,700 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-01 | A | 130 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-01 | A | 130 | 113 | 14,739 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-01 | A | 138 | 0 | 0 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-01 | A | 138 | 113 | 15,646 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-01 | A | 164 | 113 | 18,594 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-01 | A | 138 | 0 | 0 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-01 | A | 138 | 113 | 15,646 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 150 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 25,000 | 8 | 206,750 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-09-01 | A | 164 | 0 | 0 | Common | Form 4 ↗ |
| William Guyer | Chief Development Officer | 2026-09-01 | A | 164 | 113 | 18,594 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 2,281 | 116 | 263,711 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 10,989 | 115 | 1,260,568 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-01 | A | 164 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | A | 150 | 113 | 17,007 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-01 | D | 11,730 | 114 | 1,336,459 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 58,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 23,600 | 109 | 2,580,674 | Common, open-market sale | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-02 | D | 91 | 113 | 10,318 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 23,770 | 111 | 2,631,349 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 102 | 113 | 11,565 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,537 | 111 | 171,181 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-02 | D | 72 | 113 | 8,163 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 5,621 | 115 | 644,042 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,606 | 114 | 182,632 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 974 | 112 | 109,474 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | A | 58,333 | 22 | 1,261,743 | Common | Form 4 ↗ |
| Atabak Mokari | Chief Financial Officer | 2026-09-02 | D | 102 | 113 | 11,565 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-09-02 | D | 117 | 113 | 13,265 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-02 | D | 1,225 | 115 | 141,413 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 2,596 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | A | 2,596 | 11 | 29,465 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 2,188 | 114 | 249,686 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | A | 7,404 | 14 | 100,398 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 7,404 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-09-14 | D | 7,812 | 113 | 885,261 | Common, open-market sale | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 6,800 | 110 | 749,835 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 400 | 111 | 44,335 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-09-15 | D | 2,800 | 112 | 312,771 | Common, indirect | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-09-16 | D | 296 | 101 | 29,843 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-17 | A | 17,493 | 8 | 144,667 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-17 | D | 17,493 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | A | 5,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | A | 5,000 | 0 | 0 | Common | Form 4 ↗ |
| Charles Robb | Chief Business Officer | 2026-09-24 | D | 17,100 | 0 | 0 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-01 | D | 413 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-01 | A | 413 | 8 | 3,416 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-01 | D | 810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-01 | D | 810 | 115 | 93,473 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-01 | A | 810 | 14 | 10,984 | Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-01 | D | 413 | 116 | 47,717 | Common, open-market sale | Form 4 ↗ |
| Justin Frederick Gunn | See Remarks | 2026-10-01 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 24,587 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 8,744 | 117 | 1,019,143 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | D | 15,843 | 116 | 1,839,741 | Common, open-market sale | Form 4 ↗ |
| Sean Maduck | See Remarks | 2026-10-02 | A | 24,587 | 8 | 203,334 | Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 8,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 5,147 | 117 | 600,063 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 2,086 | 116 | 241,412 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | D | 1,100 | 115 | 125,973 | Common, open-market sale | Form 4 ↗ |
| Roberto Wandenkolk Vieira | President, Oncology | 2026-10-02 | A | 8,333 | 22 | 180,243 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 5,833 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 3,357 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 4,744 | 117 | 552,869 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | D | 4,446 | 116 | 514,389 | Common, open-market sale | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | A | 5,833 | 19 | 112,344 | Common | Form 4 ↗ |
| Joseph Douglas Lyon | See Remarks | 2026-10-02 | A | 3,357 | 14 | 45,521 | Common | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 300 | 116 | 34,889 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 3,046 | 115 | 351,476 | Common, indirect | Form 4 ↗ |
| James N. Wilson | Director | 2026-10-15 | D | 6,654 | 114 | 761,717 | Common, indirect | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Charles Robb | OPTION | 2025-02-28 | — | — | 140,000 | — | $5,163,087 |
| Joseph Belanoff | OPTION | 2025-02-28 | — | — | 350,000 | — | 12,907,718 |
| William Guyer | OPTION | 2025-02-28 | — | — | 140,000 | — | 5,163,087 |
| Sean Maduck | OPTION | 2025-02-28 | — | — | 140,000 | — | 5,163,087 |
| Atabak Mokari | OPTION | 2025-02-28 | — | — | 140,000 | — | 5,163,087 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Charles Robb | $0 | $0 | $5,163,087 | 0.0% |
| Joseph Belanoff | 0 | 0 | 12,907,718 | 0.0% |
| William Guyer | 0 | 0 | 5,163,087 | 0.0% |
| Sean Maduck | 0 | 0 | 5,163,087 | 0.0% |
| Atabak Mokari | 0 | 0 | 5,163,087 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| William Guyer | Option | 110,834 | 60.58 | — |
| Sean Maduck | Option | 8,334 | 19.26 | — |
| Sean Maduck | Option | 4,167 | 22.05 | — |
| Joseph Belanoff | Option | 20,834 | 19.26 | — |
| Sean Maduck | Option | 58,334 | 23.06 | — |
| Charles Robb | RSU | 224 | — | 7,795 |
| Sean Maduck | Option | 108,334 | 23.01 | — |
| Sean Maduck | Option | 110,834 | 60.58 | — |
| Charles Robb | Option | 58,334 | 23.06 | — |
| Atabak Mokari | Option | 4,167 | 19.26 | — |
| Joseph Belanoff | Option | 277,084 | 60.58 | — |
| Atabak Mokari | Option | 58,334 | 23.06 | — |
| Atabak Mokari | RSU | 178 | — | 6,194 |
| Atabak Mokari | Option | 108,334 | 23.01 | — |
| Atabak Mokari | RSU | 775 | — | 26,970 |
| Charles Robb | RSU | 997 | — | 34,696 |
| Sean Maduck | RSU | 888 | — | 30,902 |
| Atabak Mokari | Option | 110,834 | 60.58 | — |
| Charles Robb | RSU | 292 | — | 10,162 |
| Sean Maduck | RSU | 266 | — | 9,257 |
| Charles Robb | RSU | 251 | — | 8,735 |
| Atabak Mokari | RSU | 232 | — | 8,074 |
| Charles Robb | Option | 8,334 | 19.26 | — |
| Sean Maduck | RSU | 228 | — | 7,934 |
| William Guyer | RSU | 224 | — | 7,795 |
| Sean Maduck | RSU | 205 | — | 7,134 |
| Atabak Mokari | RSU | 200 | — | 6,960 |
| Joseph Belanoff | Option | 145,834 | 23.06 | — |
| Joseph Belanoff | Option | 270,834 | 23.01 | — |
| William Guyer | Option | 4,167 | 19.26 | — |
| William Guyer | Option | 58,334 | 23.06 | — |
| William Guyer | Option | 108,334 | 23.01 | — |
| Charles Robb | Option | 108,334 | 23.01 | — |
| Charles Robb | Option | 110,834 | 60.58 | — |
The company aims to offer competitive compensation that rewards good short-term and long-term performance, aligning executive and stockholder interests. Because drug development takes many years, the largest portion of named executives' compensation consists of option grants with extended vesting periods to reward long-term stockholder value creation.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | The company has an insider trading policy that prohibits named executive officers and Board members from engaging in short sales and derivative securities related to the company's stock. |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 72,511,429 | 4,560,385 | 222,643 | 94.08% | Passed |
| 2025 | 2025-06-10 | 72,914,293 | 4,195,859 | 284,923 | 94.56% | Passed |
| 2024 | 2024-05-17 | 64,501,372 | 1,018,089 | 358,666 | 98.45% | Passed |
| 2023 | 2023-05-19 | 69,095,025 | 1,450,799 | 235,570 | 97.62% | Passed |
| 2020 | 2020-05-27 | 76,887,975 | 5,808,900 | 305,179 | 92.98% | Passed |
| 2017 | 2017-05-24 | 75,561,267 | 4,089,353 | 93,419 | 94.87% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 94.08%a |
| 2025 | 2025-06-10 | 94.56%b |
| 2024 | 2024-05-17 | 98.45%c |
a. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.
b. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.
c. Approved under the standard stated in the filing — “As a result, only " FOR " votes will affect the outcome, and any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 46 : 1 |
|---|---|
| CEO total compensation | $15,303,551 |
| Median employee compensation | $334,040 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James N. WilsonIndependent · Board Chair · Nominating/Governance | $122,907 | — | $1,170,007 | — | $0 | $1,292,914 |
| Gregg AltonIndependent · Audit · Compensation | 85,000 | — | 702,004 | — | 0 | 787,004 |
| David L. MahoneyIndependent · Audit · Compensation (Chair) | 82,500 | — | 702,004 | — | 0 | 784,504 |
| Gillian M. CannonIndependent · Audit · Departed during FY | 53,259 | — | 702,004 | — | 15,241 | 770,504 |
| G. Leonard Baker JrIndependent · Compensation · Nominating/Governance | 66,000 | — | 702,004 | — | 0 | 768,004 |
| Kimberly ParkIndependent · Audit · Nominating/Governance | 62,990 | — | 702,004 | — | 0 | 764,994 |
| Joshua M. MurrayIndependent · Audit | 62,500 | — | 702,004 | — | 0 | 764,504 |
| Daniel N. Swisher JrIndependent · Compensation | 60,000 | — | 702,004 | — | 0 | 762,004 |
| Joseph K. BelanoffEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $15,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $595,156 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $15,241 |
| Total cost of the board | $610,397 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corcept Therapeutics | 2025 | Joseph Belanoff | $1,182,333 | $0 | $12,907,718 | $0 | $15,303,551 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Joseph Belanoff | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Executive Compensation”. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 2 | Section 01, Charles Robb | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Executive Compensation”. As printed: 6,380,500. Filing ↗machine: span 333502–333511 |
| 3 | Section 01, William Guyer | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Executive Compensation”. As printed: 6,340,445. Filing ↗machine: span 296081–296090 |
| 4 | Section 01, Sean Maduck | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Executive Compensation”. As printed: 6,208,642. Filing ↗machine: span 308454–308463 |
| 5 | Section 01, Atabak Mokari | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Executive Compensation”. As printed: 6,135,667. Filing ↗machine: span 320975–320984 |
| 6 | Section 03, Charles Robb OPTION | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r14 · c13 · span 331671–331680 |
| 7 | Section 03, Joseph Belanoff OPTION | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r2 · c13 · span 281411–281421 |
| 8 | Section 03, William Guyer OPTION | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r5 · c13 · span 294263–294272 |
| 9 | Section 03, Sean Maduck OPTION | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r8 · c13 · span 306623–306632 |
| 10 | Section 03, Atabak Mokari OPTION | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t17 · r11 · c13 · span 319145–319154 |
| 11 | Section 07, pay ratio | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “CEO Pay Ratio”. As printed: 46 : 1. Filing ↗machine: span 653452–653462 |
| 12 | Section 08, James N. Wilson | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 1,292,914. Filing ↗machine: span 784977–785111 |
| 13 | Section 08, Gregg Alton | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 787,004. Filing ↗machine: span 787699–787831 |
| 14 | Section 08, David L. Mahoney | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 784,504. Filing ↗machine: span 795986–796118 |
| 15 | Section 08, Gillian M. Cannon | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 770,504. Filing ↗machine: span 793290–793422 |
| 16 | Section 08, G. Leonard Baker Jr | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 768,004. Filing ↗machine: span 790400–790532 |
| 17 | Section 08, Kimberly Park | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 764,994. Filing ↗machine: span 801375–801507 |
| 18 | Section 08, Joshua M. Murray | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 764,504. Filing ↗machine: span 798682–798814 |
| 19 | Section 08, Daniel N. Swisher Jr | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 762,004. Filing ↗machine: span 804077–804209 |
| 20 | Section 08, Joseph K. Belanoff | DEF 14A | 2026-04-17 | 0001628280-26-025735 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 02, Charles Robb 2026-05-13 | Form 4 | 2026-05-15 | 0001193125-26-227411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Charles Robb 2026-05-13 | Form 4 | 2026-05-15 | 0001193125-26-227411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Charles Robb 2026-05-13 | Form 4 | 2026-05-15 | 0001193125-26-227411 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Joshua M. Murray 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239699 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Daniel N. Swisher Jr 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239705 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, James N. Wilson 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239707 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Gregg Alton 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239714 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, G. Leonard Baker Jr 2026-05-21 | Form 4 | 2026-05-26 | 0001201715-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Kimberly Park 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239683 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, David L. Mahoney 2026-05-21 | Form 4 | 2026-05-26 | 0001193125-26-239691 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, James N. Wilson 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248953 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Charles Robb 2026-05-27 | Form 4 | 2026-07-08 | 0001193125-26-298871 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Sean Maduck 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, James N. Wilson 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248953 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Joseph Douglas Lyon 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248977 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, James N. Wilson 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248953 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Sean Maduck 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Sean Maduck 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Sean Maduck 2026-05-27 | Form 4 | 2026-05-29 | 0001193125-26-248967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Joseph K. Belanoff 2026-05-29 | Form 4 | 2026-06-02 | 0001193125-26-253459 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Joseph K. Belanoff 2026-05-29 | Form 4 | 2026-06-02 | 0001193125-26-253459 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Joseph K. Belanoff 2026-05-29 | Form 4 | 2026-06-02 | 0001193125-26-253459 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Joseph K. Belanoff 2026-06-01 | Form 4 | 2026-06-02 | 0001193125-26-253459 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Charles Robb 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Atabak Mokari 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Atabak Mokari 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Atabak Mokari 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, William Guyer 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Joseph Douglas Lyon 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Atabak Mokari 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Atabak Mokari 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, William Guyer 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Joseph Douglas Lyon 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Sean Maduck 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Charles Robb 2026-06-01 | Form 4 | 2026-06-03 | 0001193125-26-256002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Atabak Mokari 2026-06-02 | Form 4 | 2026-06-03 | 0001193125-26-256011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Sean Maduck 2026-06-02 | Form 4 | 2026-06-03 | 0001193125-26-256013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, William Guyer 2026-06-02 | Form 4 | 2026-06-04 | 0001193125-26-257618 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Charles Robb 2026-06-02 | Form 4 | 2026-06-03 | 0001193125-26-256002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Joseph Douglas Lyon 2026-06-02 | Form 4 | 2026-06-03 | 0001193125-26-256022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, William Guyer 2026-06-02 | Form 4 | 2026-06-04 | 0001193125-26-257618 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, William Guyer 2026-06-02 | Form 4 | 2026-06-04 | 0001193125-26-257618 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Atabak Mokari 2026-06-15 | Form 4 | 2026-06-17 | 0001193125-26-274224 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, James N. Wilson 2026-06-16 | Form 4 | 2026-06-18 | 0001193125-26-275964 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, James N. Wilson 2026-06-16 | Form 4 | 2026-06-18 | 0001193125-26-275964 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, David L. Mahoney 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275963 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Sean Maduck 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296296 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Sean Maduck 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296296 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Sean Maduck 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296296 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Sean Maduck 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296296 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Sean Maduck 2026-07-01 | Form 4 | 2026-07-06 | 0001193125-26-296296 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, William Guyer 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, William Guyer 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, William Guyer 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, William Guyer 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298865 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, James N. Wilson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, James N. Wilson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Atabak Mokari 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, James N. Wilson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, James N. Wilson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Atabak Mokari 2026-07-30 | Form 4 | 2026-08-03 | 0001193125-26-330668 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Joseph Douglas Lyon 2026-08-03 | Form 4 | 2026-08-05 | 0001193125-26-335605 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Sean Maduck 2026-08-03 | Form 4 | 2026-08-05 | 0001193125-26-335617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Sean Maduck 2026-08-03 | Form 4 | 2026-08-05 | 0001193125-26-335617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Sean Maduck 2026-08-03 | Form 4 | 2026-08-05 | 0001193125-26-335617 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, William Guyer 2026-08-04 | Form 4 | 2026-08-06 | 0001193125-26-338637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, William Guyer 2026-08-04 | Form 4 | 2026-08-06 | 0001193125-26-338637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, William Guyer 2026-08-04 | Form 4 | 2026-08-06 | 0001193125-26-338637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, William Guyer 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346942 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, William Guyer 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346942 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Sean Maduck 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Sean Maduck 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Sean Maduck 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346951 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, William Guyer 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346942 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, William Guyer 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346942 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Charles Robb 2026-08-12 | Form 4 | 2026-08-14 | 0001193125-26-352428 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Charles Robb 2026-08-12 | Form 4 | 2026-08-14 | 0001193125-26-352428 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Charles Robb 2026-08-12 | Form 4 | 2026-08-14 | 0001193125-26-352428 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, James N. Wilson 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355562 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, James N. Wilson 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355562 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Sean Maduck 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355563 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, James N. Wilson 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355562 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Sean Maduck 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355563 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Sean Maduck 2026-08-14 | Form 4 | 2026-08-18 | 0001193125-26-355563 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Charles Robb 2026-08-17 | Form 4 | 2026-08-18 | 0001193125-26-355560 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Charles Robb 2026-08-17 | Form 4 | 2026-08-18 | 0001193125-26-355560 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, David L. Mahoney 2026-08-18 | Form 4 | 2026-08-20 | 0001193125-26-359255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, David L. Mahoney 2026-08-18 | Form 4 | 2026-08-20 | 0001193125-26-359255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, David L. Mahoney 2026-08-18 | Form 4 | 2026-08-20 | 0001193125-26-359255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, David L. Mahoney 2026-08-18 | Form 4 | 2026-08-20 | 0001193125-26-359255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Sean Maduck 2026-08-25 | Form 4 | 2026-08-27 | 0001193125-26-371388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Sean Maduck 2026-08-25 | Form 4 | 2026-08-27 | 0001193125-26-371388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Sean Maduck 2026-08-25 | Form 4 | 2026-08-27 | 0001193125-26-371388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Sean Maduck 2026-08-25 | Form 4 | 2026-08-27 | 0001193125-26-371388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Kimberly Park 2026-08-26 | Form 4 | 2026-08-28 | 0001193125-26-374607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Kimberly Park 2026-08-26 | Form 4 | 2026-08-28 | 0001193125-26-374607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Kimberly Park 2026-08-26 | Form 4 | 2026-08-28 | 0001193125-26-374607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Kimberly Park 2026-08-26 | Form 4 | 2026-08-28 | 0001193125-26-374607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Joseph Douglas Lyon 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382450 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Joseph Douglas Lyon 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382450 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Roberto Wandenkolk Vieira 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Roberto Wandenkolk Vieira 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Charles Robb 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382457 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Atabak Mokari 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382463 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Atabak Mokari 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382463 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, William Guyer 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382475 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, William Guyer 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382475 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Charles Robb 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382457 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Sean Maduck 2026-09-01 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Charles Robb 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382457 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Joseph Douglas Lyon 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382450 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Atabak Mokari 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382463 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Sean Maduck 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Roberto Wandenkolk Vieira 2026-09-02 | Form 4 | 2026-09-03 | 0001193125-26-382456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Joseph Douglas Lyon 2026-09-14 | Form 4 | 2026-09-16 | 0001193125-26-393125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, James N. Wilson 2026-09-15 | Form 4 | 2026-09-16 | 0001193125-26-393124 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, James N. Wilson 2026-09-15 | Form 4 | 2026-09-16 | 0001193125-26-393124 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, James N. Wilson 2026-09-15 | Form 4 | 2026-09-16 | 0001193125-26-393124 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Roberto Wandenkolk Vieira 2026-09-16 | Form 4 | 2026-09-18 | 0001193125-26-395837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Charles Robb 2026-09-17 | Form 4 | 2026-09-18 | 0001193125-26-395827 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Charles Robb 2026-09-17 | Form 4 | 2026-09-18 | 0001193125-26-395827 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Charles Robb 2026-09-24 | Form 4 | 2026-09-28 | 0001193125-26-405402 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Charles Robb 2026-09-24 | Form 4 | 2026-09-28 | 0001193125-26-405402 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Charles Robb 2026-09-24 | Form 4 | 2026-09-28 | 0001193125-26-405402 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Sean Maduck 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Sean Maduck 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Joseph Douglas Lyon 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Joseph Douglas Lyon 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Joseph Douglas Lyon 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Sean Maduck 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Justin Frederick Gunn 2026-10-01 | Form 4 | 2026-10-05 | 0001193125-26-414667 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Sean Maduck 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Sean Maduck 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Sean Maduck 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Sean Maduck 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414674 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Roberto Wandenkolk Vieira 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Roberto Wandenkolk Vieira 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Roberto Wandenkolk Vieira 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Roberto Wandenkolk Vieira 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Roberto Wandenkolk Vieira 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Joseph Douglas Lyon 2026-10-02 | Form 4 | 2026-10-05 | 0001193125-26-414684 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, James N. Wilson 2026-10-15 | Form 4 | 2026-10-16 | 0001193125-26-424350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, James N. Wilson 2026-10-15 | Form 4 | 2026-10-16 | 0001193125-26-424350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, James N. Wilson 2026-10-15 | Form 4 | 2026-10-16 | 0001193125-26-424350 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 06, 2026 vote | Form 8-K | 2026-05-28 | 0001628280-26-038793 | Item 5.07 · say-on-pay result. As reported: 94.08% (votes for as printed: 72,511,429). Filing ↗ |
| 222 | Section 06, 2025 vote | Form 8-K | 2025-06-16 | 0001628280-25-031624 | Item 5.07 · say-on-pay result. As reported: 94.56% (votes for as printed: 72,914,293). Filing ↗ |
| 223 | Section 06, 2024 vote | Form 8-K | 2024-05-23 | 0001628280-24-024936 | Item 5.07 · say-on-pay result. As reported: 98.45% (votes for as printed: 64,501,372). Filing ↗ |
| 224 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 225 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 226 | Section 09b board cost (computed) | Computed | — | — | Cash 595,156 + equity 0 + all other 15,241 = 610,397, summed across the director compensation table rows.machine: formula: Σ = 610,397 |
| 227 | Corcept Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.